Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.55 |
| ▸ | LPL | P06858 | 1/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.48 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.48 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
| ▸ | NQO2 | P16083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18588465 | 0.94 | LIPG (0.49) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL2144320 | 0.93 | LIPG (0.51) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL29591259 | 0.86 | PRMT5 (0.57) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL2592478 | 0.86 | PRMT5 (0.57) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL16947897 | 0.86 | LPL (0.51) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL15584874 | 0.86 | LIPG (0.46) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL16169736 | 0.84 | PRMT5 (0.46) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL4124783 | 0.84 | CA12 (0.48) | PRMT5WDR77AAK1 | |
| SCHEMBL16014297 | 0.84 | PRMT5 (0.48) | LIPGLPLPRMT5WDR77AAK1 | |
| SCHEMBL17606848 | 0.83 | PRMT5 (0.46) | LIPGLPLPRMT5WDR77AAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. | 2015-03-12 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| US-8796275-B2 | Anti-malarial compounds | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-08-05 | — | — | US | disclosed |
| EP-2321275-A1 | ANTI-MALARIAL COMPOUNDS | Polymedix, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| US-20100081665-A1 | Anti-Malarial Compounds | CELLCEUTIX CORPORATION | 2010-04-01 | — | — | US | disclosed |
| WO-2010014573-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014573-A1 | ANTI-MALARIAL COMPOUNDS | POLYMEDIX, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100081665-A1 | Anti-Malarial Compounds | AADAC, ME2, HTRA2 | LIPG 3310/4885LPL 3185/4885PRMT5 1428/4885 |
| US-20150072997-A1 | ANTI-MALARIAL COMPOUNDS | AADAC, ME2, HTRA2 | LIPG 3310/4885LPL 3185/4885PRMT5 1428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.